Taking Stelara By Stealth? Amgen Stays Silent On US Ustekinumab Launch

While Amgen had been expected to launch its Wezlana interchangeable biosimilar to Stelara from 1 January in the US, the firm has so far been quiet on details – including on the pricing strategy for its rival to the $10bn+ brand.